TEST:

Leukemia Fusion Genes Screening and Genotyping Kit

The innovative approach of the Leukemia Fusion Gene Kit is to target the gene mutations, the clonogenic gene rearrangements and abnormal gene expression. Monitor and evaluate the treatment effect in order to adjust the treatment plan in time. Regular MRD monitoring can provide early warning of recurrence, so as to strengthen treatment in time and improve survival rate. The Zeesan approach allows the screening of up to 55 types of leukemia fusion genes. The screening allows a more precise medication, precisely targeting the relevant genes. This allows a timely adjustment of treatment schedule and signals potential relapse warnings.